Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer (IV REXBC 02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00351858
Recruitment Status : Terminated (company focus on other projects)
First Posted : July 13, 2006
Last Update Posted : May 1, 2015
Information provided by:
Neovii Biotech

Brief Summary:
The purpose of this study is to determine the safety and efficacy of the investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab as treatment for hormone therapy refractory Her-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer

Condition or disease Intervention/treatment Phase
Breast Neoplasms Breast Cancer Drug: ertumaxomab Phase 2

Detailed Description:
A multi-centre, phase II study of ertumaxomab in metastatic breast cancer patients who became progressive after hormonal therapy. Each eligible patient will receive three ascending doses of ertumaxomab, administered intravenously. Ertumaxomab will be administered as a 3-hour constant rate infusion with a dosing interval of 7 days. Each patient will participate in this study for up to 7 months (includes the up to 21 days screening period, 14 days treatment period, and up to 180 days/6 months follow-up), with 3-monthly post-study follow-up until the patient becomes progressive.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of the Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab for Hormone Therapy Refractory Patients With Her-2/Neu 1+ or 2+ Expressing Advanced or Metastatic Breast Cancer
Study Start Date : July 2006
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. To demonstrate clinical efficacy of the investigational trifunctional antibody ertumaxomab for the treatment of hormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV) which are known to express Her-2/neu (1+ or 2+)

Secondary Outcome Measures :
  1. Time to progression
  2. Duration of response
  3. Time to response
  4. Clinical benefit of ertumaxomab (defined as the rate of confirmed complete remission, partial remission and stable disease)
  5. Tumor marker levels (CA 15-3 and CEA)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female gender, and if of child-bearing potential must have negative pregnancy test result within 2 days before enrolment and must agree to practice effective birth control during the study.
  • Aged 18 years and older.
  • Histologically or cytologically confirmed invasive breast cancer with stage IIIb or IV disease with documented progression.
  • Measurable disease according to RECIST.
  • Histologically documented advanced primary breast cancer or biopsy of metastatic site demonstrating HER-2/neu expression (HER-2/neu 1+ or 2+, determined by immunohistochemistry [IHC]). HER-2/neu 2+ patients must have a negative Fluorescence In Situ Hybridization [FISH] test result.
  • Hormone receptor status Estrogen Receptors (ERs) positive and/or Progesterone Receptors (PRs) positive.
  • No prior treatment with mouse or rat antibodies.
  • Life expectancy of at least six months (if the life expectancy of a patient is unspecified she will be allowed to enter the study).
  • An Eastern Cooperative Oncology Group (ECOG) performance score of £ 1.
  • Patients must have had disease progression after hormonal therapy including at least one aromatase inhibitor.
  • Adequate hematological, liver and kidney function:

    • Thrombocytes ³ 100000 / mm³ (= 100 x 109 /l)
    • Hemoglobin ³ 10 g/dl
    • Neutrophil count ³ 1500/mm³ (= 1.5 x 109 /l)
    • WBC ³ 3 X 109 /l
    • Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT) ≤ 2.5 x upper limit of normal (ULN)
    • Serum bilirubin ≤ 2 x ULN
    • Creatinine ≤ 1.5 x ULN or clearance ³ 60 ml/min
  • No life-threatening visceral disease.
  • No known brain or central nervous system metastases.
  • No symptomatic pleural effusions.
  • No symptomatic pericardial effusions.
  • No subjects whose only site of metastatic involvement is bone metastases with the exception of those with a measurable soft tissue component of the bone lesion seen with imaging that does not require palliative radiation intervention and/or the patient has a lytic bone lesion ³ 1 cm measured with radiography that can be followed for evidence of re-calcification.
  • No history of relevant cardiovascular disease:

    • LVEF within the institutional ranges of normal as measured by echocardiogram or MUGA scan
    • No prior uncontrolled or symptomatic congestive heart failure NYHA ³ 2
    • No myocardial infarction within the past two years
    • No uncontrolled or symptomatic cardiac arrhythmias
  • No severe dyspnea.
  • No pulmonary dysfunction or need for continuous supportive oxygen inhalation.
  • No other concurrent uncontrolled co-morbid illness.
  • No other concurrent malignancy, except treated basal cell or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix.
  • Patients with documented autoimmune diseases (such as lupus) are excluded from participation in the study unless a waiver is granted by the responsible medical monitor.
  • Patients with a human immunodeficiency virus, hepatitis B or hepatitis C positive status are excluded from participation in the study.
  • No prior or concurrent chemotherapy regimen for advanced or metastatic disease.
  • Prior neo-adjuvant or adjuvant chemotherapy is allowed provided it was stopped at least six months before study entry.
  • No concurrent hormone therapy (hormone therapy must be stopped at the screening visit).
  • At least 4 weeks since prior radiotherapy.
  • No concurrent immune therapy.
  • No concurrent corticosteroid therapy.
  • No regularly used medication for a health condition or comorbidity that might result in undue risk to the patient.
  • No prior investigational treatment for advanced or metastatic disease.
  • Able and willing to comply fully with the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00351858

Layout table for location information
Jules Bordet Institute, Free University of Brussels
Brussels, Belgium, 1000
Sponsors and Collaborators
Neovii Biotech
Layout table for investigator information
Principal Investigator: Fatima Cardoso, MD Brussels

Layout table for additonal information Identifier: NCT00351858    
Other Study ID Numbers: FBT-IVREXBC 02
EudraT number: 2005-004294-21
First Posted: July 13, 2006    Key Record Dates
Last Update Posted: May 1, 2015
Last Verified: April 2015
Keywords provided by Neovii Biotech:
Breast Cancer
investigational drug
drug therapy
Antineoplastic Protocols
Metastatic breast cancer
Advanced breast cancer
Stage III to IV breast cancer
Hormonal therapy refractory
Failure of hormonal therapy
Her-2/neu expressing breast cancer
low to moderate Her-2/neu expression
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs